117 results on '"Shiffman, Mitchell L."'
Search Results
2. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC
3. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
4. Sa1462: THE HEPQUANT SHUNT DISEASE SEVERITY INDEX (HEPQUANT DSI™) CAN AID THE DECISION TO AVOID ENDOSCOPIC SCREENING OR SURVEILLANCE FOR VARICES NEEDING TREATMENT
5. Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus
6. Challenging Issues in the Management of Chronic Hepatitis B Virus
7. Preface
8. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
9. 686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDY
10. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
11. Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment
12. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy
13. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
14. Mo1468 – Long Term Assessment of the Effects of Obeticholic Acid in Patients with Primary Biliary Cholangitis on Immune and Inflammatory Markers
15. 953 – High Efficacy and Improvement in Cpt Class with Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients with Cpt C Decompensated Cirrhosis
16. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo
17. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options
18. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis
19. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
20. 625 - The Negative Impact of Diabetes Mellitus on Continued Fibrosis Progression Despite Hepatitis C Virus Treatment is Amplified in the Setting of Obesity
21. Mo1454 - Durable Response in the Markers of Cholestasis Through 36 Months of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis
22. Mo1450 - Change in Bilirubin with Obeticholic Acid Treatment in Primary Biliary Cholangitis Patients with High Baseline Bilirubin: A Retrospective Analysis of Poise, 201, and 202
23. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease
24. Selected Summary
25. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
26. Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis
27. Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of Phase 3 Studies
28. Management of hepatitis C virus infection in the Asia-Pacific region: an update
29. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response
30. Sa1579 Durable Response in the Markers of Cholestasis through 18 Months of Open-Label Long Term Safety Extension Study of Obeticholic Acid in Primary Biliary Cirrhosis
31. Su1415 The Tolerability of Sof/VEL for 12 Weeks in >1000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis
32. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection
33. Long term changes in liver histology following treatment of chronic hepatitis C virus
34. My Treatment Approach to Chronic Hepatitis C Virus
35. Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)
36. Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy
37. Print and Digital Media Review
38. Managing the Complications of Cirrhosis: A Practical Approach
39. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
40. Rate of Progression of Hepatic Fibrosis in Patients With Chronic Hepatitis C: Results From the HALT-C Trial
41. Interferon-Free Regimens: The Near Future, the Likely and the Not So Likely
42. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
43. Gender Differences in Hepatitis C Virus (HCV) Treatment Outcomes With Peginterferon (pegIFN) Plus Ribavirin (RBV): An Analysis of the IDEAL Study
44. Thyroid Stimulating Hormone (TSH) and Peginterferon Treatment Induced Hypothyroidism May Be Associated With Phosphodiesterase Polymorphisms in Patients With Chronic Hepatitis C
45. Infections During Peginterferon (pegIFN)/Ribavirin (RBV) Therapy Are Associated With a Decline in Lymphocyte Count: Results of the IDEAL Study
46. Reply
47. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
48. Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads
49. Similar Progression of Fibrosis Between HIV/HCV–Infected and HCV–Infected Patients: Analysis of Paired Liver Biopsy Samples
50. Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.